FDA Patent Listing Procedures May Need Revision, Hatch And Waxman Say
Executive Summary
FDA should apply more judgment in analyzing patents submitted for listing in the "Orange Book" when generic competition is imminent, Sens. Kennedy (D-Mass.) and Hatch (R-Utah) and Rep. Waxman (D-Calif.) said in a letter to HHS Secretary Thompson.
You may also be interested in...
FDA Waxman/Hatch “Moot Court” Will Examine Brand/Generic Legal Positions
FDA's chief counsel will be hosting a "moot court" to receive a thorough briefing on the brand and generic industry arguments about the agency's interpretation of the Waxman/Hatch Act
FDA Waxman/Hatch “Moot Court” Will Examine Brand/Generic Legal Positions
FDA's chief counsel will be hosting a "moot court" to receive a thorough briefing on the brand and generic industry arguments about the agency's interpretation of the Waxman/Hatch Act
Patent Extensions’ Cost To Be Evaluated By FDA Under Ag Approps Request
FDA will report on the costs to consumers of drug patent extensions by March